38576039|t|An adapted protocol to derive microglia from stem cells and its application in the study of CSF1R-related disorders.
38576039|a|BACKGROUND: Induced pluripotent stem cell-derived microglia (iMGL) represent an excellent tool in studying microglial function in health and disease. Yet, since differentiation and survival of iMGL are highly reliant on colony-stimulating factor 1 receptor (CSF1R) signaling, it is difficult to use iMGL to study microglial dysfunction associated with pathogenic defects in CSF1R. METHODS: Serial modifications to an existing iMGL protocol were made, including but not limited to changes in growth factor combination to drive microglial differentiation, until successful derivation of microglia-like cells from an adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) patient carrying a c.2350G > A (p.V784M) CSF1R variant. Using healthy control lines, the quality of the new iMGL protocol was validated through cell yield assessment, measurement of microglia marker expression, transcriptomic comparison to primary microglia, and evaluation of inflammatory and phagocytic activities. Similarly, molecular and functional characterization of the ALSP patient-derived iMGL was carried out in comparison to healthy control iMGL. RESULTS: The newly devised protocol allowed the generation of iMGL with enhanced transcriptomic similarity to cultured primary human microglia and with higher scavenging and inflammatory competence at ~ threefold greater yield compared to the original protocol. Using this protocol, decreased CSF1R autophosphorylation and cell surface expression was observed in iMGL derived from the ALSP patient compared to those derived from healthy controls. Additionally, ALSP patient-derived iMGL presented a migratory defect accompanying a temporal reduction in purinergic receptor P2Y12 (P2RY12) expression, a heightened capacity to internalize myelin, as well as heightened inflammatory response to Pam3CSK4. Poor P2RY12 expression was confirmed to be a consequence of CSF1R haploinsufficiency, as this feature was also observed following CSF1R knockdown or inhibition in mature control iMGL, and in CSF1RWT/KO and CSF1RWT/E633K iMGL compared to their respective isogenic controls. CONCLUSIONS: We optimized a pre-existing iMGL protocol, generating a powerful tool to study microglial involvement in human neurological diseases. Using the optimized protocol, we have generated for the first time iMGL from an ALSP patient carrying a pathogenic CSF1R variant, with preliminary characterization pointing toward functional alterations in migratory, phagocytic and inflammatory activities.
38576039	92	97	CSF1R	Gene	1436
38576039	178	182	iMGL	CellLine	CVCL:YE48
38576039	310	314	iMGL	CellLine	CVCL:YE48
38576039	337	373	colony-stimulating factor 1 receptor	Gene	1436
38576039	375	380	CSF1R	Gene	1436
38576039	416	420	iMGL	CellLine	CVCL:YE48
38576039	430	452	microglial dysfunction	Disease	MESH:D006331
38576039	491	497	CSF1R.	Gene	1436
38576039	543	547	iMGL	CellLine	CVCL:YE48
38576039	743	784	leukoencephalopathy with axonal spheroids	Disease	MESH:C580150
38576039	789	803	pigmented glia	Disease	MESH:D010859
38576039	805	809	ALSP	Disease	MESH:C580150
38576039	811	818	patient	Species	9606
38576039	830	841	c.2350G > A	DNAMutation	tmVar:c|SUB|G|2350|A;HGVS:c.2350G>A;VariantGroup:1;CorrespondingGene:1436;RS#:690016564;CorrespondingSpecies:9606;CA#:346102
38576039	843	850	p.V784M	ProteinMutation	tmVar:p|SUB|V|784|M;HGVS:p.V784M;VariantGroup:1;CorrespondingGene:1436;RS#:690016564;CorrespondingSpecies:9606;CA#:346102
38576039	852	857	CSF1R	Gene	1436
38576039	919	923	iMGL	CellLine	CVCL:YE48
38576039	1088	1100	inflammatory	Disease	MESH:D007249
38576039	1188	1192	ALSP	Disease	MESH:C580150
38576039	1193	1200	patient	Species	9606
38576039	1209	1213	iMGL	CellLine	CVCL:YE48
38576039	1263	1267	iMGL	CellLine	CVCL:YE48
38576039	1331	1335	iMGL	CellLine	CVCL:YE48
38576039	1396	1401	human	Species	9606
38576039	1443	1455	inflammatory	Disease	MESH:D007249
38576039	1562	1567	CSF1R	Gene	1436
38576039	1632	1636	iMGL	CellLine	CVCL:YE48
38576039	1654	1658	ALSP	Disease	MESH:C580150
38576039	1659	1666	patient	Species	9606
38576039	1730	1734	ALSP	Disease	MESH:C580150
38576039	1735	1742	patient	Species	9606
38576039	1751	1755	iMGL	CellLine	CVCL:YE48
38576039	1842	1847	P2Y12	Gene	64805
38576039	1849	1855	P2RY12	Gene	64805
38576039	1936	1948	inflammatory	Disease	MESH:D007249
38576039	1961	1969	Pam3CSK4	Chemical	-
38576039	1976	1982	P2RY12	Gene	64805
38576039	2031	2036	CSF1R	Gene	1436
38576039	2101	2106	CSF1R	Gene	1436
38576039	2149	2153	iMGL	CellLine	CVCL:YE48
38576039	2162	2169	CSF1RWT	Gene	1436
38576039	2177	2184	CSF1RWT	Gene	1436
38576039	2185	2190	E633K	ProteinMutation	tmVar:p|SUB|E|633|K;HGVS:p.E633K;VariantGroup:0;CorrespondingGene:1436;RS#:281860269;CorrespondingSpecies:9606;CA#:342706
38576039	2191	2195	iMGL	CellLine	CVCL:YE48
38576039	2285	2289	iMGL	CellLine	CVCL:YE48
38576039	2362	2367	human	Species	9606
38576039	2368	2389	neurological diseases	Disease	MESH:D020271
38576039	2458	2462	iMGL	CellLine	CVCL:YE48
38576039	2471	2475	ALSP	Disease	MESH:C580150
38576039	2476	2483	patient	Species	9606
38576039	2506	2511	CSF1R	Gene	1436
38576039	2623	2635	inflammatory	Disease	MESH:D007249
38576039	Association	MESH:C580150	RS#:690016564;HGVS:c.2350G>A;CorrespondingGene:1436
38576039	Positive_Correlation	RS#:690016564;HGVS:c.2350G>A;CorrespondingGene:1436	MESH:C580150
38576039	Association	MESH:D006331	1436
38576039	Association	MESH:C580150	RS#:690016564;HGVS:p.V784M;CorrespondingGene:1436
38576039	Association	1436	64805
38576039	Negative_Correlation	MESH:C580150	64805
38576039	Association	MESH:C580150	1436

